Valuation -- 5/10
| Company | Market Cap | Trailing P/E | Fwd P/E | EV/EBITDA | Div Yield |
|---|---|---|---|---|---|
| Clorox (CLX) | $12.2B | 16.5x | ~17x | ~12x | 4.90% |
| Procter & Gamble (PG) | ~$380B | ~21x | ~23x | ~16x | ~2.4% |
| Church & Dwight (CHD) | ~$22B | ~33x | ~27x | ~22x | ~1.1% |
| Spectrum Brands (SPB) | -- | ~17x | ~13x | ~7x | ~1.7% |
| Sector Median | -- | ~20x | ~20x | ~15x | ~2.5% |
| Key Takeaway | CLX trades at the deepest discount in the peer group on P/E and EV/EBITDA, reflecting ERP disruption and category headwinds. The 4.9% yield is highest among peers. Median analyst target $121 implies ~20% upside (range $94-$163). | ||||
| # | Catalyst | Timeline | Magnitude | Probability |
|---|---|---|---|---|
| 1 | FY27 ERP normalization (~$0.90 EPS add-back) | Jul 2026+ | High | High (85%) |
| Management confirmed 7.5 pts of negative sales headwind and ~$0.90 EPS drag from ERP transition reverses mechanically in FY27. Digital transformation investment adjustment ends after FQ3 26 (~$0.08). Single largest near-term earnings catalyst. | ||||
| 2 | GOJO/Purell integration ($2.25B acquisition) | Completed Apr 2026 | Mod-High | Moderate (65%) |
| ~$800M sales, mid-single-digit growth CAGR. Strengthens Health & Wellness segment. Net purchase price ~$1.92B after tax benefits. Accretive to growth algorithm. Execution risk exists but team is experienced. | ||||
| 3 | Back-half innovation pipeline | Q3-Q4 FY26 | Moderate | Moderate (60%) |
| Pure Allergen platform (new category), Glad Leakguard, full Fresh Step/Scoop Away relaunch, Hidden Valley price-pack architecture. Shelf resets Q3-early Q4. Management calling this the strongest innovation pipeline in years. | ||||
| 4 | Glad JV termination benefit | H2 FY26 | Low-Mod | High (90%) |
| ~50 bps gross margin tailwind in back half from Glad JV termination, not present in H1. Mechanical and predictable. | ||||
| 5 | Category growth re-acceleration to 2-2.5% | FY27-28 | High | Low-Mod (40%) |
| Ignite algorithm assumes 2-2.5% category growth + 1 pt from pro/international. Currently running flat to +1%. Consumer stress and promotional environment need to ease. | ||||
| 6 | Dividend yield support / oversold technical | Near-term | Low-Mod | High (80%) |
| 4.9% yield near 52-week lows with RSI ~32. Income-oriented investors provide floor. Stock down ~33% from 52-week highs. | ||||
| 7 | Supply chain / ERP-driven cost savings | FY27+ | Moderate | Moderate (55%) |
| Management targeting 25-50 bps annual EBIT margin expansion from new digital infrastructure. Automation, global business services, end-to-end supply chain visibility. | ||||
| # | Risk | Severity | Probability | Mitigant |
|---|---|---|---|---|
| 1 | Tariff headwinds (~$40-100M+) | HIGH | High (75%) | $40M in FY26 guidance; exploring sourcing changes to offset ~$100M hit. Resin, sodium hypochlorite, soybean oil all exposed. Escalation risk is the fat tail. |
| 2 | Prolonged consumer weakness / category stagnation | HIGH | Moderate (55%) | Categories running flat vs historical 2-2.5%. Low-income consumers under pressure. Brita and Bleach flagged as areas management is watching carefully. |
| 3 | GOJO integration / leverage risk | MOD-HIGH | Moderate (45%) | $2.25B cash deal adds meaningful leverage during core business recovery. TD Cowen flagged management distraction risk. Integration costs could exceed plan. |
| 4 | Household segment margin compression | MEDIUM | High (70%) | Household EBIT margins fell to 5.3% in Q2 FY26. Intense competition from private label and branded peers in trash bags and cat litter. Negative price/mix for 3+ quarters. |
| 5 | Input cost inflation (~$70M FY26) | MEDIUM | Moderate (60%) | Resin, non-woven fabrics, sodium hypochlorite, corrugated, soybean oil. Commodity tailwinds have reversed. Any oil/resin spike would pressure margins further. |
| 6 | Innovation execution risk (back-half loaded) | MEDIUM | Moderate (50%) | H2 heavily weighted to innovation launch success. Double typical investment behind Pure Allergen -- high conviction but high stakes in a value-seeking environment. |
| 7 | Analyst sentiment deterioration | LOW-MED | Moderate (55%) | Hold consensus from 11 analysts. BofA cut to $110, Deutsche Bank cut to $101 (at current price). Further estimate cuts could pressure shares below 52-week lows. |
| 8 | Price/mix headwinds persist | MEDIUM | High (65%) | ~1 pt negative price/mix guided for FY26 from consumer value-seeking and channel shifting (grocery to club/dollar). CEO explicitly not taking price investment off the table. |
- FY27 EPS normalizes to ~$7.00+ as $0.90 ERP drag reverses and GOJO adds ~$0.20-0.30
- Gross margin recovery toward 45%+ as ERP costs fade and cost savings accelerate
- Innovation pipeline drives category and share recovery; categories re-accelerate to 2%+
- P/E re-rates toward 18-20x on improved growth visibility
- 4.9% yield provides floor; stock is near oversold (RSI ~32)
- Tariffs escalate beyond $100M; input costs spike on resin/oil
- Category growth stalls at 0% as consumer recession deepens
- GOJO integration stumbles; leverage constrains flexibility
- Household segment (Glad, Litter) continues market share bleed despite innovation
- P/E compresses to 13-14x on earnings misses; dividend cut risk if FCF erodes
- FY26 EPS comes in at low end of guidance (~$5.95 adj.)
- FY27 EPS recovers to ~$6.80-7.00 on ERP normalization + GOJO contribution
- Gross margins stabilize; back-half innovation shows moderate traction
- Categories remain flat to +1%; share recovery is gradual
- P/E ~17x on FY27 estimates = ~$115-120 target
Score of 5/10 reflects balanced risk/reward with meaningful near-term headwinds offset by improving catalysts into FY27. The valuation discount to peers already embeds significant pessimism, but near-term earnings visibility is poor and the tariff environment adds fat-tail risk that is difficult to quantify.
Why not higher (6-7): The tariff overhang ($40-100M+) is material and evolving. Household segment margins are badly compressed at 5.3% EBIT. Category growth is stagnant and depends on consumer health that is deteriorating. GOJO adds leverage during a transition year. Three consecutive quarters of negative price/mix with no clear inflection. Analyst sentiment is negative (Hold consensus, targets being cut toward current price). The innovation pipeline is promising but unproven -- heavy back-half loading raises execution risk.
Why not lower (3-4): The ERP normalization is mechanical and highly visible -- $0.90/share reversal into FY27 provides a clear earnings catalyst. GOJO/Purell is a strategically sound acquisition in a growing category (skin health/hygiene). Gross margin compression is largely transitory (ERP costs, logistics). The 4.9% dividend yield at 52-week lows provides downside support. IGNITE cost savings program has a strong multi-year track record. Private label penetration remains manageable -- not a structural share loss story. The valuation discount to peers (16.5x vs CHD at 33x, PG at 21x) already embeds significant pessimism.
Net assessment: CLX is a fundamentally sound business going through a trough in both earnings and sentiment. The catalysts (ERP normalization, GOJO, innovation) are real but face legitimate headwinds (tariffs, consumer weakness, Household segment competitive pressure). The dividend yield and valuation discount provide a margin of safety, but near-term earnings visibility is poor. A score of 5 reflects this equilibrium. AVOID / Watchlist.